New Malvern Data Demonstrate Monoclonal Antibody Characterisation Using the Viscotek SEC-MALS 20
Malvern Instruments has posted a new application note demonstrating the use of the company’s Viscotek SEC-MALS 20 multi angle light scattering (MALS) detector for size exclusion chromatography (SEC) in the analysis of monoclonal antibodies.
The application note, ‘Molecular weight measurements of an antibody using Viscotek SEC-MALS 20’, reports experimental data for the analysis of aggregates within monoclonal antibody formulations.
Monoclonal antibodies are being targeted for use in a growing range of therapeutic applications. Measuring the molecular weight of the protein, monomer, oligomers and aggregates within the sample and in formulations is an important part of assessing their safety and efficacy as drugs. Light scattering techniques allow the measurement of absolute molecular weight without relying on potentially inaccurate calibration methods, with MALS an established technology within the industry.
When added to a GPC/SEC chromatography system, the new Viscotek SEC-MALS 20 delivers market-leading MALS detector performance with high accuracy, even at high molecular weights. Its launch makes the Malvern Instruments Viscotek light scattering detector range the broadest available, allowing the company to offer unbiased, optimised solutions for any GPC/SEC application.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
.png)
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.